On May 15, 2020 MV BioTherapeutics reported the launch of the company website that provides most relevant information on the technology and pipeline of MV BioTherapeutics (Press release, MV BioTherapeutics, MAY 15, 2020, View Source [SID1234632273]). We have changed the original name of the company from MicroVaccines to MV BioTherapeutics (from now on MV).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During the past years we have developed therapeutic live biotherapeutics with different mode of action as compared to the original live attenuated microbial vaccines, which were exemplified as microvaccines" says Dr. Fabio Grassi, founder and Chairman of MV.

"With two lead indications and potential future developments of this promising application, it was important to characterize the company as non-exclusively dedicated to vaccines that is a very specific pharmaceutical area."

The abbreviation MV is directly related to the two patented microorganisms ApyraMed and ApyraVax